Advertisement
Singapore markets closed
  • Straits Times Index

    3,426.47
    -3.98 (-0.12%)
     
  • Nikkei

    37,667.41
    -202.10 (-0.53%)
     
  • Hang Seng

    17,021.31
    +16.34 (+0.10%)
     
  • FTSE 100

    8,285.71
    +99.36 (+1.21%)
     
  • Bitcoin USD

    68,833.76
    +1,437.80 (+2.13%)
     
  • CMC Crypto 200

    1,390.12
    +59.51 (+4.47%)
     
  • S&P 500

    5,459.10
    +59.88 (+1.11%)
     
  • Dow

    40,589.34
    +654.27 (+1.64%)
     
  • Nasdaq

    17,357.88
    +176.16 (+1.03%)
     
  • Gold

    2,385.70
    +32.20 (+1.37%)
     
  • Crude Oil

    76.44
    -1.84 (-2.35%)
     
  • 10-Yr Bond

    4.2000
    -0.0560 (-1.32%)
     
  • FTSE Bursa Malaysia

    1,612.88
    -2.30 (-0.14%)
     
  • Jakarta Composite Index

    7,288.17
    +47.89 (+0.66%)
     
  • PSE Index

    6,726.01
    +55.74 (+0.84%)
     

AbbVie Should Consider a Dividend Cut -- Here's Why

AbbVie Should Consider a Dividend Cut -- Here's Why

Since its split from Abbott Laboratories in 2013, AbbVie (NYSE: ABBV) has been the third best-performing stock in terms of total returns on capital (assuming the dividend was reinvested) on the esteemed list of Dividend Kings. AbbVie's top-shelf performance has been due to two main factors. First up, the company successfully expanded Humira's label at a breakneck pace over this period, transforming it into the world's first pharma product to exceed $20 billion a year in sales.